Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

97.19
-1.1800-1.20%
Post-market: 97.190.00000.00%19:44 EDT
Volume:874.17K
Turnover:85.59M
Market Cap:9.43B
PE:41.57
High:100.00
Open:99.00
Low:97.06
Close:98.37
Loading ...

Company Profile

Company Name:
Sarepta Therapeutics
Exchange:
NASDAQ
Establishment Date:
1980
Employees:
1372
Office Location:
215 First Street,Suite 415,Cambridge,Massachusetts,United States
Zip Code:
02142
Fax:
- -
Introduction:
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
M. Kathleen Behrens
Director and Chairwoman of the Board of Directors
Claude Nicaise
Director
Gil Price
Director
Hans Wigzell
Director
Jean Paul Kress
Director
Richard J. Barry
Director
William A. Goolsbee
Director

Shareholders

Name
Position
Edward M. Kaye
Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer
David Tyronne Howton
Senior Vice President, General Counsel and Corporate Secretary
Jayant Aphale
Senior Vice President, Technical Operations
Sandesh Mahatme
Senior Vice President, Chief Financial Officer